192 related articles for article (PubMed ID: 21700731)
1. Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy.
Campone M; Bondarenko I; Brincat S; Hotko Y; Munster PN; Chmielowska E; Fumoleau P; Ward R; Bardy-Bouxin N; Leip E; Turnbull K; Zacharchuk C; Epstein RJ
Ann Oncol; 2012 Mar; 23(3):610-617. PubMed ID: 21700731
[TBL] [Abstract][Full Text] [Related]
2. Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.
Moy B; Neven P; Lebrun F; Bellet M; Xu B; Sarosiek T; Chow L; Goss P; Zacharchuk C; Leip E; Turnbull K; Bardy-Bouxin N; Duvillié L; Láng I
Oncologist; 2014 Apr; 19(4):348-9. PubMed ID: 24674874
[TBL] [Abstract][Full Text] [Related]
3. Bosutinib in combination with the aromatase inhibitor exemestane: a phase II trial in postmenopausal women with previously treated locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.
Moy B; Neven P; Lebrun F; Bellet M; Xu B; Sarosiek T; Chow L; Goss P; Zacharchuk C; Leip E; Turnbull K; Bardy-Bouxin N; Duvillié L; Láng I
Oncologist; 2014 Apr; 19(4):346-7. PubMed ID: 24674873
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors.
Daud AI; Krishnamurthi SS; Saleh MN; Gitlitz BJ; Borad MJ; Gold PJ; Chiorean EG; Springett GM; Abbas R; Agarwal S; Bardy-Bouxin N; Hsyu PH; Leip E; Turnbull K; Zacharchuk C; Messersmith WA
Clin Cancer Res; 2012 Feb; 18(4):1092-100. PubMed ID: 22179664
[TBL] [Abstract][Full Text] [Related]
5. Bosutinib: a novel second-generation tyrosine kinase inhibitor.
Isfort S; Keller-v Amsberg G; Schafhausen P; Koschmieder S; Brümmendorf TH
Recent Results Cancer Res; 2014; 201():81-97. PubMed ID: 24756786
[TBL] [Abstract][Full Text] [Related]
6. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.
Kantarjian HM; Cortes JE; Kim DW; Khoury HJ; Brümmendorf TH; Porkka K; Martinelli G; Durrant S; Leip E; Kelly V; Turnbull K; Besson N; Gambacorti-Passerini C
Blood; 2014 Feb; 123(9):1309-18. PubMed ID: 24345751
[TBL] [Abstract][Full Text] [Related]
7. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.
Cortes JE; Gambacorti-Passerini C; Deininger MW; Mauro MJ; Chuah C; Kim DW; Dyagil I; Glushko N; Milojkovic D; le Coutre P; Garcia-Gutierrez V; Reilly L; Jeynes-Ellis A; Leip E; Bardy-Bouxin N; Hochhaus A; Brümmendorf TH
J Clin Oncol; 2018 Jan; 36(3):231-237. PubMed ID: 29091516
[TBL] [Abstract][Full Text] [Related]
8. Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib.
Cortes JE; Khoury HJ; Kantarjian HM; Lipton JH; Kim DW; Schafhausen P; Matczak E; Leip E; Noonan K; Brümmendorf TH; Gambacorti-Passerini C
Am J Hematol; 2016 Dec; 91(12):1206-1214. PubMed ID: 27531525
[TBL] [Abstract][Full Text] [Related]
9. Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia.
Stansfield L; Hughes TE; Walsh-Chocolaad TL
Ann Pharmacother; 2013 Dec; 47(12):1703-11. PubMed ID: 24396109
[TBL] [Abstract][Full Text] [Related]
10. Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma.
Taylor JW; Dietrich J; Gerstner ER; Norden AD; Rinne ML; Cahill DP; Stemmer-Rachamimov A; Wen PY; Betensky RA; Giorgio DH; Snodgrass K; Randall AE; Batchelor TT; Chi AS
J Neurooncol; 2015 Feb; 121(3):557-63. PubMed ID: 25411098
[TBL] [Abstract][Full Text] [Related]
11. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.
Khoury HJ; Cortes JE; Kantarjian HM; Gambacorti-Passerini C; Baccarani M; Kim DW; Zaritskey A; Countouriotis A; Besson N; Leip E; Kelly V; Brümmendorf TH
Blood; 2012 Apr; 119(15):3403-12. PubMed ID: 22371878
[TBL] [Abstract][Full Text] [Related]
12. Benefits and risks of ponatinib versus bosutinib following treatment failure of two prior tyrosine kinase inhibitors in patients with chronic phase chronic myeloid leukemia: a matching-adjusted indirect comparison.
Levy MY; McGarry LJ; Huang H; Lustgarten S; Chiroli S; Iannazzo S
Curr Med Res Opin; 2019 Mar; 35(3):479-487. PubMed ID: 30086654
[TBL] [Abstract][Full Text] [Related]
13. Bosutinib for the treatment of chronic myeloid leukemia.
Doan V; Wang A; Prescott H
Am J Health Syst Pharm; 2015 Mar; 72(6):439-47. PubMed ID: 25736937
[TBL] [Abstract][Full Text] [Related]
14. Bosutinib treatment for Philadelphia chromosome-positive leukemias.
Bethelmie-Bryan B; Lord K; Holloway S; Khoury HJ
Future Oncol; 2014 Feb; 10(2):179-85. PubMed ID: 24490604
[TBL] [Abstract][Full Text] [Related]
15. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.
Gambacorti-Passerini C; Brümmendorf TH; Kim DW; Turkina AG; Masszi T; Assouline S; Durrant S; Kantarjian HM; Khoury HJ; Zaritskey A; Shen ZX; Jin J; Vellenga E; Pasquini R; Mathews V; Cervantes F; Besson N; Turnbull K; Leip E; Kelly V; Cortes JE
Am J Hematol; 2014 Jul; 89(7):732-42. PubMed ID: 24711212
[TBL] [Abstract][Full Text] [Related]
16. A phase 1/2 study of bosutinib in Japanese adults with Philadelphia chromosome-positive chronic myeloid leukemia.
Nakaseko C; Takahashi N; Ishizawa K; Kobayashi Y; Ohashi K; Nakagawa Y; Yamamoto K; Miyamura K; Taniwaki M; Okada M; Kawaguchi T; Shibata A; Fujii Y; Ono C; Ohnishi K
Int J Hematol; 2015 Feb; 101(2):154-64. PubMed ID: 25540064
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study.
Gambacorti-Passerini C; Cortes JE; Lipton JH; Kantarjian HM; Kim DW; Schafhausen P; Crescenzo R; Bardy-Bouxin N; Shapiro M; Noonan K; Leip E; DeAnnuntis L; Brümmendorf TH; Khoury HJ
Haematologica; 2018 Aug; 103(8):1298-1307. PubMed ID: 29773593
[TBL] [Abstract][Full Text] [Related]
18. Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Syed YY; McCormack PL; Plosker GL
BioDrugs; 2014 Feb; 28(1):107-20. PubMed ID: 24420842
[TBL] [Abstract][Full Text] [Related]
19. Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib.
Brümmendorf TH; Cortes JE; Khoury HJ; Kantarjian HM; Kim DW; Schafhausen P; Conlan MG; Shapiro M; Turnbull K; Leip E; Gambacorti-Passerini C; Lipton JH
Br J Haematol; 2016 Jan; 172(1):97-110. PubMed ID: 26537529
[TBL] [Abstract][Full Text] [Related]
20. Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the Spanish compassionate use program.
García-Gutiérrez V; Martinez-Trillos A; Lopez Lorenzo JL; Bautista G; Martin Mateos ML; Alvarez-Larrán A; Iglesias Pérez A; Romo Collado A; Fernandez A; Portero A; Cuevas B; Ruiz C; Romero E; Ortega F; Mata I; Tallón J; García Garay Mdel C; Ramirez Sánchez MJ; de Las Heras N; Giraldo P; Bobillo S; Guinea JM; Deben G; Valencia S; Sebrango A; Boqué C; Maestro B; Steegmann JL
Am J Hematol; 2015 May; 90(5):429-33. PubMed ID: 25683327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]